Read the original:

scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh